We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic Test for Malaria Evaluated

By LabMedica International staff writers
Posted on 14 Sep 2017
The ability of individuals to carry low-density malaria infections and have minimal clinical symptoms is believed to be the consequence of exposure-related clinical immunity, resulting in the suppression of parasitemia, and has been observed in both high- and low-transmission settings.

Although laboratory assays, such as polymerase chain reactions (PCR) and enzyme-linked immunosorbent assays (ELISA) are more sensitive than microscopy and rapid diagnostic tests (RDTs), they are also more expensive, require highly trained personnel, take longer to produce results, and are more difficult to deploy for large-scale field use.

A large team of scientist led by those at Diagnostics Program, PATH, (Seattle, WA, USA) evaluated the performance of a new ultra-sensitive RDT (uRDT) using whole blood specimens collected from asymptomatic individuals in Uganda, and a Karen village in Myanmar, representing high- and low-transmission settings, as well as from naive individuals enrolled in Plasmodium falciparum induced blood-stage malaria (IBSM) challenge studies.

The scientists evaluated the Alere Malaria Ag P.f Ultra-Sensitive RDT, which was developed for field use and evaluated for detection of low-density infections and compared with as compared with the currently available SD Bioline Malaria Ag P.f RDT. More...
A quantitative reverse transcription PCR (qRT-PCR) and a highly sensitive ELISA test for histidine-rich protein II (HRP2) were used as reference assays.

The investigators reported that the uRDT showed a greater than 10-fold lower limit of detection for HRP2 compared with the RDT. The sensitivity of the uRDT was 84% and 44% against qRT-PCR in Uganda and Myanmar, respectively, and that of the RDT was 62% and 0% for the same two sites. The specificities of the uRDT were 92% and 99.8% against qRT-PCR for Uganda and Myanmar, respectively, and 99% and 99.8% against the HRP2 reference ELISA. The RDT had specificities of 95% and 100% against qRT-PCR for Uganda and Myanmar, respectively, and 96% and 100% against the HRP2 reference ELISA. The uRDT detected new infections in IBSM study participants 36 hours sooner than the RDT. The uRDT has the same workflow as currently available RDTs, but improved performance characteristics to identify asymptomatic malaria infections.

The authors concluded that the improved performance characteristics of the Alere Malaria Ag P.f. uRDT over the current malaria RDTs in asymptomatic patients from Myanmar and Uganda, as well as naïve participants in the IBSM studies are highly indicative of the utility of this test as a tool for malaria elimination. The study was published in the August 2017 issue of the American Journal of Tropical Medical Hygiene.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.